Plain-language summary
======================

Everolimus improved the median progression-free survival by 7.1 months vs placebo among patients with advanced, well-differentiated, nonfunctional neuroendocrine tumors of gastrointestinal or lung origin in the RADIANT-4 study. The present post hoc analysis of the phase III, randomized, placebo-controlled, RADIANT-4 study demonstrates a clinically meaningful improvement in progression-free survival in East Asian patients with advanced, progressive, nonfunctional neuroendocrine tumors of lung or gastrointestinal origin. In addition, the safety of everolimus in the East Asian subgroup was consistent with the known safety profile of everolimus.

Introduction
============

Neuroendocrine tumors (NETs) are a group of rare heterogeneous malignancies that arise from neuroendocrine cells found throughout the body.[@b1-ott-12-1717] Tumors associated with hormonal symptoms due to excessive secretion of hormones and peptides are termed functional NETs, whereas those not associated with hormonal symptoms are considered nonfunctional. The majority of NETs are nonfunctional, and most commonly arise in the gastrointestinal (GI) and bronchopulmonary regions.[@b2-ott-12-1717] An epidemiological analysis revealed that carcinoid syndrome is significantly associated with the primary tumor site, grade, and stage.[@b3-ott-12-1717] Understanding the complex cell biology and tumor heterogeneity associated with NETs could facilitate a tailored approach to improve patient survival.[@b3-ott-12-1717] According to the US population-based Surveillance, Epidemiology, and End Results (SEER) database, the annual age-adjusted incidence of NETs showed a 6.4-fold increase -- from 1.1 in 100,000 in 1973 to 7.0 in 100,000 in 2012 -- and continues to grow irrespective of tumor site, stage, and grade.[@b4-ott-12-1717] Incidence rates were higher for gastroenteropancreatic (GEP) NETs (3.6 in 100,000) than lung NETs (1.5 in 100,000), followed by unknown primary (0.8 in 100,000) as per the SEER 18 registry (2000--2012).[@b4-ott-12-1717] Overall survival rates increased from 2000--2004 to 2009--2012, wherein patients had a 21.3% of reduced risk of death (HR 0.79, 95% CI 0.73--0.85). Similar trends have been observed in distant-stage GI NETs.[@b4-ott-12-1717]

The reason for this rise in incidence is unknown, although a variety of underlying factors, including improved diagnostic methods, are suspected.[@b3-ott-12-1717] In 2010, the prevalence and annual incidence rates of GI NETs in Japanese patients were 6.4 in 100,000 and 3.5 in 100,000, respectively.[@b5-ott-12-1717] A nationwide survey reported a much higher frequency of GI NETs among Japanese patients than was reported in Western countries.[@b4-ott-12-1717] The incidence rate of NETs in Taiwan was not well known until Tsai et al published their surveys, which showed a fivefold increase from 0.3 in 100,000 in 1996 to 1.5 in 100,000 in 2008.[@b6-ott-12-1717] A single-center study[@b7-ott-12-1717] conducted in South Korea estimated the incidence of NETs to be 24.1 in 100,000, which is comparatively much higher than the population-based rate (2.9--5.9 in 100,000).[@b1-ott-12-1717],[@b8-ott-12-1717] These epidemiological data suggest that ethnic differences, including possible differences in hormone production or other characteristics, may have a role in the clinical presentation of disease; however, potential ethnic differences in the evaluation of drug therapies for NETs have not been studied extensively.[@b7-ott-12-1717]

In 2015, the Japan Neuroendocrine Tumor Society established consensus guidelines for the diagnosis and management of Japanese patients with GEP NETs. These guidelines focus primarily on identifying the disease stage and highlight the importance of an evidence-based treatment approach for the treatment of Japanese patients with GEP NETs.[@b8-ott-12-1717]

Surgery is the mainstay of treatment of localized and locoregional NETs of GI or lung origin, and no adjuvant therapy is required. Somatostatin analogues (SSAs), including octreotide and lanreotide, are the current gold standard and a widely used treatment option to control the symptoms of functional NETs.[@b9-ott-12-1717] Furthermore, long-acting octreotide has also demonstrated antiproliferative activity in patients with well-differentiated, unresectable, metastatic midgut NETs in the randomized, double-blind, placebo-controlled, multicenter PROMID study.[@b10-ott-12-1717] In addition, findings from the CLARINET study[@b11-ott-12-1717] led to the approval of long-acting lanreotide 120 mg for the treatment of Japanese patients with GEP NETs.[@b12-ott-12-1717] Additional treatment options include hepatic arterial embolization, radioembolization, peptide-receptor radionuclide therapy, and chemoembolization.

The mTOR pathway is an essential cellular signaling pathway that serves as a central modulator of cell metabolism, proliferation, growth, and survival. Aberrant activation of mTOR by PI3K/Akt has been identified in a wide range of cancers, including NETs.[@b13-ott-12-1717] Everolimus (an oral mTOR inhibitor) has demonstrated significant activity in the randomized phase III studies RADIANT-3 and RADIANT-4.[@b14-ott-12-1717],[@b15-ott-12-1717] In the RADIANT-4 study, everolimus showed a 52% reduction in risk of disease progression or death (HR 0.48, 95% CI 0.35--0.67), with median progression-free survival (PFS) improved by 7.1 months in patients with advanced, well-differentiated, nonfunctional NETs of GI or lung origin compared with placebo. Based on this study's findings, everolimus received approval for the treatment of progressive, unresectable, or metastatic, well-differentiated, nonfunctional NETs of the GI tract or lung.[@b16-ott-12-1717] Further, everolimus is also approved for the treatment of patients with advanced or metastatic, unresectable, progressive pancreatic NETs.[@b17-ott-12-1717] This present analysis aimed to explore the efficacy and safety of everolimus in the East Asian subgroup of the RADIANT-4 study.

Methods
=======

Study design and treatment
--------------------------

RADIANT-4 was an international, multicenter, randomized, double blind, placebo-controlled, phase III study (NCT01524783) conducted in 97 centers in 25 countries worldwide. For the East Asian-subgroup analysis, patients were included from 20 centers in five countries (China, Japan, South Korea, Taiwan, and Thailand; [Figure 1](#f1-ott-12-1717){ref-type="fig"}). Patients aged \$18 years with pathologically confirmed, advanced, nonfunctional, well-differentiated NETs of lung or GI origin with documented disease progression within 6 months before randomization were eligible for inclusion.

Additional inclusion criteria included measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, World Health Organization (WHO) performance status (0 or 1), and adequate bone-marrow, liver, and kidney function. Patients were ineligible if they had a history of or presented with carcinoid syndrome, poorly differentiated histology, or pancreatic NETs, and had received more than one line of chemotherapy, previous treatment with mTOR inhibitors (sirolimus, temsirolimus, or everolimus), hepatic intra-arterial embolization within 6 months of randomization, cryoablation or radiofrequency ablation of hepatic metastases within 2 months of randomization, or chronic treatment with corticosteroids or other immunosuppressive agents. The details of RADIANT-4 inclusion and exclusion criteria have been reported previously.[@b15-ott-12-1717]

The study followed the guiding principles of the Declaration of Helsinki, Good Clinical Practice guidelines, and local regulations. The study was approved by each center's institutional review boards or independent ethics committees (Supplementary material). All patients provided written informed consent. An independent data-monitoring committee reviewed safety-related data and provided oversight in study conduct.

Patients were randomly allocated (2:1) to receive everolimus (oral, 10 mg/day) or matching placebo, both with best supportive care, until disease progression or occurrence of an intolerable adverse event (AE) or consent withdrawal. Treatment was continued until disease progression or occurrence of an intolerable AE or consent withdrawal. An interactive voice-response system was used to randomize the patients. Randomization was stratified based on prior SSA treatment (defined as continuous SSA treatment for \$12 weeks), tumor origin (based on prognostic level, grouped into two strata: stratum A \[better prognosis\], appendix, cecum, jejunum, ileum, duodenum, or NETs of unknown primary; stratum B \[worse prognosis\], lung, stomach, colon \[other than cecum\], or rectum), and WHO performance status 0 or 1. Dose reductions and treatment interruptions were permitted for the occurrence of any treatment-related AEs and for a maximum of 28 days. Crossover from the placebo to open-label everolimus upon disease progression was not permitted, and the investigators remained blinded to treatment assignment until the primary analysis.[@b15-ott-12-1717]

Assessments
-----------

The primary efficacy end point was PFS as per central review, defined as the time from randomization to death or progression according to RECIST version 1.0. Secondary end points comprised overall response rate (defined as proportion of patients with best overall response of complete response \[CR\] or partial response \[PR\]), disease-control rate (defined as the proportion of patients with best overall response of CR, PR, or stable disease, safety, and tolerability. An exploratory analysis of this study included an evaluation of population pharmacokinetic (PK) data.

The primary efficacy analysis was performed on an intent-to-treat basis, whereas the safety set included all patients who had received at least one dose of the study drug with at least one postbaseline safety assessment. AEs were reported as per National Cancer Institute Common Terminology Criteria for AEs version 4.03.[@b15-ott-12-1717] A predose PK blood sample was collected in all patients by direct venipuncture prior to dosing on day 29. The number of blood samples available for PK analysis was limited, and only valid blood samples (confirmed blood samples collected at steady state, immediately prior to dosing on the same study day, approximately 24±4 hours after the previous dose, and with no vomiting within the first 4 hours following the last dose) were considered.

Statistical analyses
--------------------

By central radiology review, PFS was analyzed using Kaplan--Meier methods, as reported previously.[@b15-ott-12-1717] The full-analysis set (all randomized patients) was used for all efficacy analyses. Sample-size calculations were not undertaken for the cohort of patients described in this report, as this analysis was not powered to compare treatment groups. HRs and corresponding CIs were estimated using an unstratified Cox proportional-hazard model.[@b15-ott-12-1717] Steady-state condition for the minimum plasma concentration (C~min~) sample was defined as continuous administration of the same dose in the last 4 days prior to collection of the C~min~ sample. Drug concentrations for the everolimus and best-supportive-care groups were summarized by actual leading dose, ie, the dose taken on the day prior to the PK sampling day. Descriptive statistics included arithmetic and geometric mean, median, SD, CV%, geometric CV%, minimum, and maximum. Concentrations of 0 were not included in the geometric mean calculation. PK analysis was based on the safety set in patients with evaluable samples.

Results
=======

Patient demographics and disposition
------------------------------------

Of the 302 patients (everolimus, n=205; placebo, n=97) enrolled in the RADIANT-4 study who received treatment with everolimus 10 mg/day or matching placebo, 46 were included in the East Asian subgroup (everolimus, n=28; placebo, n=18; [Figure S1](#SD1-ott-12-1717){ref-type="supplementary-material"}). The median age of patients in the East Asian subgroup was 57 (22--75) years in the everolimus arm and 53 (33--72) years in the placebo arm, which was consistent with the overall RADIANT-4 population.[@b15-ott-12-1717] The details of baseline demographics and disease characteristics are included in [Table 1](#t1-ott-12-1717){ref-type="table"}.

Patient disposition is shown in [Table 2](#t2-ott-12-1717){ref-type="table"}. The median duration of exposure was 46.9 (3.1--101.4) and 40.4 (0.7--120.4) weeks for everolimus vs 13.4 (4.0--85.3) and 19.6 (4.0--130.3) weeks for placebo in the East Asian subgroup and the overall RADIANT-4 population, respectively.

A greater number of patients in the placebo arm discontinued treatment (94% in the East Asian subgroup and 87% in the overall population) compared with everolimus (68% in the East Asian subgroup and 76% in the overall population). In both the East Asian subgroup and the overall population, disease progression was the primary reason for treatment discontinuation. The proportion of patients experiencing disease progression by RECIST version 1.0 was substantially higher in the placebo arm (77.8% in the East Asian subgroup and 72.2% in the overall population) compared with everolimus (42.9% in the East Asian subgroup and 37.1% in the overall population). Other reasons for treatment discontinuation included AEs, consent withdrawal, protocol deviation, or death ([Table 2](#t2-ott-12-1717){ref-type="table"}).

Efficacy
--------

In the East Asian subgroup, everolimus was associated with an 82% reduction in estimated risk of disease progression or death (HR 0.18, 95% CI 0--0.38; [Figure 2A](#f2-ott-12-1717){ref-type="fig"}), with improved median PFS of 11.2 months (95% CI 7.33--not available; 15 events) with everolimus vs 3.1 months (95% CI 1.81--3.71; 17 events) with placebo arms. These results were consistent with the overall RADIANT-4 population, wherein everolimus was associated with a 52% reduction in risk of disease progression or death (HR 0.48, 95% CI 0.35--0.67; [Figure 2B](#f2-ott-12-1717){ref-type="fig"}), with improved median PFS of 11.0 months (95% CI 9.23--13.31; 113 events) with everolimus vs 3.9 months (95% CI 3.58--7.43; 65 events) with placebo arms.[@b15-ott-12-1717] The disease-control rate (greater than or equal to stable disease) was 93% and 44% in the everolimus and placebo arms, respectively, for the East Asian subgroup compared with 82% and 65%, respectively, for the everolimus and placebo arms in the overall population.[@b15-ott-12-1717] In the East Asian subgroup, stable disease as best response was noted in 26 (93%) and eight patients (44%) in the everolimus and placebo arms, respectively. Progressive disease as best response occurred in one patient (4%) treated with everolimus and eight patients (44%) in the placebo arm. None of the patients in the East Asian subgroup achieved CR or PR, which was consistent with efficacy for the overall RADIANT-4 population ([Table 3](#t3-ott-12-1717){ref-type="table"}). From the results of the best percentage change from baseline in the East Asian subgroup, it was observed that a greater proportion of patients experienced reduction in size of the target lesion in the everolimus arm vs placebo (72% vs 21%; [Figure 3A](#f3-ott-12-1717){ref-type="fig"}). This difference was slightly greater than observed for the overall population (64% vs 26% in the everolimus and placebo arms, respectively; [Figure 3B](#f3-ott-12-1717){ref-type="fig"}).

Safety
------

In the East Asian subgroup, AEs suspected to be related to the study drug occurred in all 28 patients (100%) who were treated with everolimus and ten (56%) who received placebo. The most frequently reported (\$30% of incidence) drug-related any-grade AEs in patients receiving everolimus in the East Asian subgroup vs the overall population were stomatitis (21 of 28 \[75%\] vs 127 of 202 \[63%\]), and rash (12 of 28 \[43%\] vs 55 of 202 \[27%\]). The majority of the AEs reported were of grade 1 or of grade 2 in severity ([Table 4](#t4-ott-12-1717){ref-type="table"}). Drug-related grade 3 or 4 AEs were reported in ten patients in the everolimus arm and two patients receiving placebo. The most common drug-related grade 3 or 4 AEs in the everolimus arm were stomatitis, anemia, and increased levels of ALT (each two of 28 \[7%\]).

In the overall population, the most common drug-related any-grade AEs occurring in \$30% of patients given everolimus were stomatitis (127 of 202 \[63%\]), diarrhea (63 of 202 \[31%\]), and fatigue (62 of 202 \[31%\]). The majority of these AEs were grade 1 or 2. The most common drug-related grade 3 or 4 AEs with everolimus included stomatitis (18 of 202 \[9%\]), diarrhea (15 of 202 \[7%\]), infections (14 of 202 \[7%\]), fatigue (seven of 202 \[3%\]), anemia (eight of 202 \[4%\]), and hyperglycemia (seven of 202 \[4%\]).[@b15-ott-12-1717]

Pharmacokinetics
----------------

A summary of everolimus PK parameters after 5 mg and 10 mg daily doses is presented in [Table S1](#SD2-ott-12-1717){ref-type="supplementary-material"}. Considering the high interpatient variability in both East Asian and non--East Asian patients, there was no apparent difference in C~min~ observed in the two subgroups after daily administration of 10 mg everolimus. Further, the everolimus C~min~ exposure among the East Asian subgroup population was found to be consistent with the overall population.

Discussion
==========

RADIANT-4 is the largest clinical study to demonstrate significant improvement in PFS in patients with advanced, progressive NETs of GI or lung origin.[@b15-ott-12-1717] However, considering the heterogeneous nature of patient population, there is a need to conduct a subgroup analysis to better understand the effect of everolimus on geographical population-based distribution.

In the present post hoc analysis of the RADIANT-4 East Asian subgroup, everolimus was associated with an 82% reduction in estimated risk of progression or death (HR 0.18, 95% CI 0.09--0.38), with improved median PFS of 11.2 months with everolimus vs 3.1 months with placebo, in patients with advanced, progressive, nonfunctional NETs of GI or lung origin. In the overall RADIANT-4 population, everolimus showed a 52% reduction in the estimated risk of progression or death (HR 0.48, 95% CI 0.35--0.67), and median PFS was prolonged by a clinically meaningful 7.1 months for patients treated with everolimus. Further, the safety of everolimus in the overall RADIANT-4 population was found to be consistent with the established safety profile.[@b15-ott-12-1717] Based on the findings from this study, everolimus has been approved worldwide for the treatment of patients with advanced, nonfunctional NETs of GI, lung, and pancreatic origin.

The reduction in risk of disease progression or death in the East Asian subgroup (82%) was greater than observed in the overall RADIANT-4 population (52%). In addition, a slightly higher proportion of patients in the East Asian subgroup experienced tumor shrinkage than the overall population. Tumor shrinkage occurred more frequently in the everolimus than placebo arms (East Asian, 72% vs 21%; overall, 64% vs 26%).[@b15-ott-12-1717]

The efficacy of everolimus was also assessed in the Japanese subgroup of the RADIANT-3 study, wherein median PFS was 19.4 months (95% CI 8.31--not available) with everolimus vs 2.8 months (95% CI 2.46--8.34) with placebo, corresponding to an 81% reduction in risk of disease progression or death (HR 0.19, 95% CI 0.08--0.48).[@b18-ott-12-1717] On the other hand, in the overall RADIANT-3 population, median PFS was 11.0 months with everolimus vs 4.6 months with placebo (HR 0.35, 95% CI 0.27--0.45), resulting in a 65% reduction in estimated risk of disease progression or death.[@b14-ott-12-1717] The favorable efficacy outcomes and tolerable safety profile in the RADIANT-3 Japanese subgroup and the RADIANT-4 East Asian subgroup populations were consistent with their respective overall study populations.

In the present East Asian subgroup of RADIANT-4, which included patients with NETs of GI and lung origin, study-drug-related AEs occurred in all patients who received everolimus and in approximately 55% of patients receiving placebo. The majority of these events were of grade 1 or of grade 2 ([Table 4](#t4-ott-12-1717){ref-type="table"}). Drug-related pneumonitis is a class-effect toxicity of rapamycin derivatives, including everolimus.[@b19-ott-12-1717] This effect has been studied in several studies conducted on patients with advanced renal-cell carcinoma, non-small-cell lung carcinoma, and advanced NETs.[@b14-ott-12-1717],[@b20-ott-12-1717],[@b21-ott-12-1717] The reported incidence rates of pneumonitis in patients with advanced renal-cell carcinoma, non-small-cell lung carcinoma, and advanced NETs were 23%--30%, 25%, and 12%, respectively.[@b14-ott-12-1717],[@b20-ott-12-1717]--[@b23-ott-12-1717]

In a phase III study of everolimus in combination with long-acting octreotide in patients with advanced NETs, the drug-related pneumonitis rate was 8%.[@b24-ott-12-1717] The incidence of pneumonitis in the everolimus arm of the East Asian subgroup of RADIANT-4 was 18%; however, none of these was severe in nature. The incidence of pneumonitis in the everolimus arm of the overall population was 14%. The majority of these were either of grade 1 or of 2 in severity. Grade 3 pneumonitis was observed in three patients. The incidence of grade 3 or 4 AEs in the East Asian patients was comparatively lower than the overall population. In general, everolimus toxicity was manageable, with no new safety signals observed during the study (incidence \$30%; East Asian subgroup, stomatitis \[75%\], rash \[43%\], and pneumonitis \[18%\]; overall population, stomatitis \[63%\], rash \[27%\], and pneumonitis \[14%\]).

Among the East Asian, non--East Asian, and overall RADIANT-4 populations, no differences in exposure in terms of C~min~ were noted after daily administration of 10 mg everolimus. However, a reduced risk of progression or death was observed in the East Asian subgroup (HR 0.18) vs the overall population (HR 0.48). A possible explanation for this reduced risk in the East Asian subset could be the longer duration of everolimus exposure in these patients (47 weeks) compared with the overall population (40 weeks) or differences in distribution of disease characteristics, such as primary site (rectum as primary site, East Asian 41% \[19 of 46\] vs overall 13% \[40 of 302\]).

Although this study was a post hoc analysis from a randomized phase III study, it is the first study of its kind specifically to include patients from the East Asian region (China, Japan, South Korea, Taiwan, and Thailand) from a phase III study on NETs. As with most subgroup analyses, this study carries some limitations: it was not powered to compare the treatment groups, was not a planned subgroup analysis, and the sample was small. Therefore, careful interpretation of data and extrapolation should be considered.

Conclusion
==========

Everolimus demonstrated a clinically meaningful improvement of PFS in East Asian patients with advanced, progressive, nonfunctional NETs of lung or GI origin enrolled in RADIANT-4. The safety profile in the East Asian subgroup was consistent with the known safety of everolimus, and no new safety signals were observed. These findings support the use of everolimus as a valuable treatment option in East Asian patients with advanced, progressive, nonfunctional NETs of lung or GI origin.

Data-sharing statement
======================

Novartis is committed to sharing with qualified external researchers access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided are anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial-data availability is according to the criteria and process described on [www.clinicalstudydatarequest.com](http://www.clinicalstudydatarequest.com).

Supplementary materials
=======================

###### 

CONSORT patient flowchart.

**Notes:** ^a^The full-analysis set comprised all 302 randomly assigned patients (205 patients in the everolimus group and 97 in the placebo group). Two patients randomly assigned to everolimus were not treated, due to withdrawal of consent and protocol deviation, and one patient randomly assigned to everolimus inadvertently received placebo treatment because of a dispensation error at the site; therefore, the safety set contains 202 patients in the everolimus group and 98 in the placebo group. ^b^At data cutoff (November 28, 2014).

###### 

Everolimus steady-state predose concentration by leading dose (safety set; valid predose samples)

  Everolimus                                                                                                    
  ----------------------------------- ---------------------- ------------ ----------- ------------- ----------- -------------
  **Predose concentration (ng/mL)**                                                                             
  Mean (SD)                           1.7 (not applicable)   17.8 (9.3)   4.7 (3.8)   16.4 (13.3)   6.2 (4.0)   15.9 (14.4)
  CV% mean                            --                     52.3         81.7        81.1          64.7        90.8
  Geometric mean                      1.7                    15.6         3.7         12.8          5.5         12.0
  CV% geometric mean                  --                     60.3         100.7       79.1          79.3        84.3
  Median                              1.7                    13.6         3.4         12.6          6.2         11.3
  Range                               1.7--1.7               5.4--33.6    1.7--9.0    2.4--72.3     3.4--9.0    2.4--72.3

**Notes:** Zero concentrations are considered as missing in geometric mean calculations. CV% mean = SD/mean × 100. Geometric mean = exp (mean log-transformed data). CV% geometric mean = √(exp \[variance for log-transformed data\] -- 1) × 100.

**Abbreviation:** CV, coefficient of variation.
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![Study design.\
**Notes:** ^a^Based on prognostic level, grouped as: stratum A (better prognosis) -- appendix, cecum, jejunum, ileum, duodenum, and NET of unknown primary; stratum B (worse prognosis) -- lung, stomach, rectum, and colon except cecum.\
**Abbreviations:** NET, neuroendocrine tumor; SSA, somatostatin analogue; WHO PS, World Health Organization performance status.](ott-12-1717Fig1){#f1-ott-12-1717}

![Kaplan--Meier plot of progression-free survival. **Notes:** (**A**) East Asian subgroup; (**B**) overall population.[@b15-ott-12-1717]\
**Abbreviations:** BSC, best supportive care; NA, not available.](ott-12-1717Fig2){#f2-ott-12-1717}

![Percentage changes from baseline in size of target lesion: central review (full-analysis set).\
**Notes:** (**A**) East Asian subgroup. (**B**) Overall population.[@b15-ott-12-1717] Patients for whom the best percentage change in target lesion was not available and patients for whom the best percentage change in target lesions was contradicted by overall lesion response of unknown were excluded from the analysis.\
**Abbreviation:** BSC, best supportive care.](ott-12-1717Fig3){#f3-ott-12-1717}

###### 

Baseline demographics, disease characteristics, and prior therapies

                                                                                East Asian subgroup   Overall population[f](#tfn6-ott-12-1717){ref-type="table-fn"}                      
  ----------------------------------------------------------------------------- --------------------- --------------------------------------------------------------- ------------------ -----------------
                                                                                                                                                                                         
  Age (years), median (range)                                                   57 (22--75)           53 (33--72)                                                     65 (22--86)        60 (24--83)
                                                                                                                                                                                         
  Female/male, n (%)                                                            18 (64)/10 (36)       6 (33)/12 (67)                                                  116 (57)/89 (43)   44 (45)/53 (55)
                                                                                                                                                                                         
  WHO PS 0, n (%)                                                               19 (68)               12 (67)                                                         149 (73)           73 (75)
                                                                                                                                                                                         
  WHO PS 1, n (%)                                                               9 (32)                6 (33)                                                          55 (27)            24 (25)
                                                                                                                                                                                         
  Primary tumor site, n (%)                                                                                                                                                              
   Rectum                                                                       11 (39)               8 (44)                                                          25 (12)            15 (16)
   Lung                                                                         5 (18)                2 (11)                                                          63 (31)            27 (28)
   Jejunum                                                                      3 (11)                0                                                               16 (8)             6 (6)
   Duodenum                                                                     3 (11)                1 (6)                                                           8 (4)              2 (2)
   Stomach                                                                      1 (4)                 2 (11)                                                          7 (3)              4 (4)
   Ileum                                                                        0                     1 (6)                                                           47 (23)            24 (25)
   CUP                                                                          3 (11)                4 (22)                                                          23 (11)            13 (13)
   Other[a](#tfn1-ott-12-1717){ref-type="table-fn"}                             2 (7)                 0                                                               6 (3)              2 (2)
                                                                                                                                                                                         
  Tumor grade (WHO grade), n (%)                                                                                                                                                         
   Grade 1                                                                      6 (21)                5 (28)                                                          129 (63)           65 (67)
   Grade 2                                                                      17 (61)               9 (50)                                                          75 (37)            32 (33)
                                                                                                                                                                                         
  Current extent of disease,[b](#tfn2-ott-12-1717){ref-type="table-fn"} n (%)                                                                                                            
   Liver                                                                        24 (86)               16 (89)                                                         163 (80)           76 (78)
   Lung                                                                         4 (14)                2 (11)                                                          45 (22)            20 (21)
   Bone                                                                         3 (11)                2 (11)                                                          42 (21)            15 (16)
   Lymph node or lymphatic system[c](#tfn3-ott-12-1717){ref-type="table-fn"}    5 (8)                 2 (11)                                                          85 (42)            45 (46)
                                                                                                                                                                                         
  Prior treatments, n (%)                                                                                                                                                                
   Surgery                                                                      15 (54)               9 (50)                                                          121 (59)           70 (72)
   Somatostatin analogues[d](#tfn4-ott-12-1717){ref-type="table-fn"}            10 (36)               5 (28)                                                          109 (53)           54 (56)
   Chemotherapy                                                                 8 (29)                4 (22)                                                          54 (26)            23 (24)
   Locoregional therapy                                                         6 (21)                3 (17)                                                          23 (11)            10 (10)
   Radiotherapy[e](#tfn5-ott-12-1717){ref-type="table-fn"}                      3 (11)                0                                                               44 (22)            19 (20)

**Notes:**

One patient in the everolimus group (overall population) had thymus as the primary site and had primary tumor origin of the gastrointestinal tract.

Time since initial diagnosis and time since most current relapse calculated relative to randomization date.

Cumulative cases of para-aortic, cervical, and thoracic lymph-node tumors.

Given mostly for tumor control, and included subcutaneous octreotide, long-acting octreotide, and long-acting lanreotide.

Includes PRRT.

Data from Yao et al.[@b15-ott-12-1717]

**Abbreviations:** CUP, cancer of unknown primary; PRRT, peptide-receptor radionuclide therapy; WHO PS, World Health Organization performance status.

###### 

Patient disposition and duration of exposure

                                                                 East Asian subgroup, n (%)   Overall population, n (%)[b](#tfn9-ott-12-1717){ref-type="table-fn"}                     
  -------------------------------------------------------------- ---------------------------- ---------------------------------------------------------------------- ----------------- -----------------
                                                                                                                                                                                       
  Treated                                                        28 (100)                     18 (100)                                                               203 (99)          97 (100)
                                                                                                                                                                                       
  Ongoing treatment[a](#tfn8-ott-12-1717){ref-type="table-fn"}   9 (32)                       1 (6)                                                                  48 (24)           13 (13)
                                                                                                                                                                                       
  Patient discontinuation                                        19 (68)                      17 (94)                                                                155 (76)          84 (87)
   Disease progression                                           12 (43)                      14 (78)                                                                76 (37)           70 (72)
   Adverse events                                                6 (21)                       0                                                                      59 (29)           7 (7)
   Consent withdrawal                                            0                            2 (11)                                                                 15 (7)            5 (5)
   Death                                                         0                            1 (6)                                                                  4 (2)             1 (1)
   Protocol deviation                                            1 (4)                        0                                                                      1 (1)             1 (1)
                                                                                                                                                                                       
  Duration of exposure (weeks), median (range)                   47 (3.1--101.4)              13 (4.0--85.3)                                                         40 (0.7--120.4)   20 (4.0--130.3)

**Notes:**

At data cutoff (November 28, 2014);

Data from Yao et al.[@b15-ott-12-1717]

###### 

Best overall response

                                   East Asian subgroup, n (%)   Overall population, n (%)[a](#tfn10-ott-12-1717){ref-type="table-fn"}                          
  -------------------------------- ---------------------------- ----------------------------------------------------------------------- ---------------------- ---------------------
  Complete response                0                            0                                                                       0                      0
  Partial response                 0                            0                                                                       4 (2)                  1 (1)
  Stable disease                   26 (93)                      8 (44)                                                                  165 (81)               62 (64)
  Progressive disease              1 (4)                        8 (44)                                                                  19 (9)                 26 (27)
  Unknown                          1 (4)                        2 (11)                                                                  17 (8)                 8 (8)
  Overall response rate (95% CI)   0 (0--12.3)                  0 (0--18.5)                                                             4 (2)(0.5--4.9)        1 (1)(0--5.6)
  Disease-control rate (95% CI)    26 (93)(76.5--99.1)          8 (44)(21.5--69.2)                                                      169 (82)(76.5--87.4)   63 (65)(54.6--74.4)

**Note:**

Data from Yao et al.[@b15-ott-12-1717]

###### 

Drug-related adverse events in the East Asian subgroup and the overall population (\$10% of incidence in either arm)

  Preferred term                                           East Asian subgroup, n (%)   Overall population, n (%)[c](#tfn13-ott-12-1717){ref-type="table-fn"}                                                      
  -------------------------------------------------------- ---------------------------- ----------------------------------------------------------------------- --------- -------- ---------- ---------- --------- ---------
  Any AEs                                                  28 (100)                     10 (36)                                                                 10 (56)   2 (11)   193 (96)   106 (53)   67 (68)   13 (13)
  Stomatitis[a](#tfn11-ott-12-1717){ref-type="table-fn"}   21 (75)                      2 (7)                                                                   3 (17)    0        127 (63)   18 (9)     19 (19)   0
  Rash                                                     12 (43)                      0                                                                       2 (11)    0        55 (27)    1 (,1)     8 (8)     0
  Pneumonitis                                              5 (18)                       0                                                                       0         0        27 (13)    3 (2)      1 (1)     0
  Infections[b](#tfn12-ott-12-1717){ref-type="table-fn"}   8 (29)                       0                                                                       1 (6)     0        59 (29)    14 (7)     4 (4)     0
  Decreased appetite                                       7 (25)                       1 (4)                                                                   1 (6)     0        32 (16)    1 (,1)     6 (6)     0
  Asthenia                                                 6 (21)                       1 (4)                                                                   1 (6)     0        33 (16)    3 (1)      5 (5)     0
  Peripheral edema                                         6 (21)                       0                                                                       0         0        52 (26)    4 (2)      4 (4)     1 (1)
  Fatigue                                                  6 (21)                       0                                                                       2 (11)    0        62 (31)    7 (3)      24 (24)   1 (1)
  Dermatitis acneiform                                     5 (18)                       0                                                                       0         0        19 (9)     0          3 (3)     0
  Pruritus                                                 5 (18)                       0                                                                       3 (17)    0        26 (13)    1 (,1)     4 (4)     0
  Epistaxis                                                4 (14)                       0                                                                       0         0        17 (8)     1 (,1)     0         0
  Diarrhea                                                 4 (14)                       0                                                                       3 (17)    1 (6)    63 (31)    15 (7)     16 (16)   2 (2)
  Hypertriglyceridemia                                     4 (14)                       0                                                                       0         0        9 (5)      1 (1)      0         0
  ALT increased                                            4 (14)                       2 (7)                                                                   1 (6)     0        9 (5)      5 (3)      1 (1)     0
  AST increased                                            4 (14)                       0                                                                       1 (6)     0        7 (4)      0          1 (1)     0
  Weight decreased                                         4 (14)                       0                                                                       0         0        16 (8)     2 (1)      4 (4)     0
  Pyrexia                                                  4 (14)                       0                                                                       0         0        22 (11)    4 (2)      5 (5)     0
  Acne                                                     3 (11)                       0                                                                       0         0        8 (4)      0          0         0
  Rash, maculopapular                                      3 (11)                       0                                                                       1 (6)     0        9 (5)      0          1 (1)     0
  Face edema                                               3 (11)                       0                                                                       0         0        5 (3)      0          0         0
  Dysgeusia                                                3 (11)                       0                                                                       0         0        30 (15)    1 (,1)     4 (4)     0
  Anemia                                                   3 (11)                       2 (7)                                                                   0         0        33 (16)    8 (4)      2 (2)     1 (1)
  Headache                                                 3 (11)                       0                                                                       0         0        14 (7)     0          6 (6)     0
  Hyperglycemia                                            3 (11)                       1 (4)                                                                   0         0        21 (10)    7 (4)      2 (2)     0
  Hypercholesterolemia                                     3 (11)                       0                                                                       0         0        11 (5)     0          1 (1)     0

**Notes:**

Included in this category are stomatitis, aphthous stomatitis, mouth ulceration, and tongue ulceration.

All types of infections included.

Data from Yao et al.[@b15-ott-12-1717]
